Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer

Maiko Niki; Aya Nakaya; Takayasu Kurata; Hiroshige Yoshioka; Toshihiko Kaneda; Kayoko Kibata; Makoto Ogata; Shosaku Nomura

doi:10.18632/oncotarget.25949

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer

Maiko Niki, Aya Nakaya _, Takayasu Kurata, Hiroshige Yoshioka, Toshihiko Kaneda, Kayoko Kibata, Makoto Ogata and Shosaku Nomura

PDF | HTML | How to cite

Oncotarget. 2018; 9:32298-32304. https://doi.org/10.18632/oncotarget.25949

Metrics: PDF 2380 views | HTML 3178 views | ?

Abstract

Maiko Niki1, Aya Nakaya1, Takayasu Kurata1, Hiroshige Yoshioka1, Toshihiko Kaneda1, Kayoko Kibata1, Makoto Ogata1 and Shosaku Nomura1

1First Department of Internal Medicine, Kansai Medical University, Shin-machi, Hirakata, Osaka 573-1010, Japan

Correspondence to:

Aya Nakaya, email: [email protected]

Keywords: immune checkpoint inhibitor; nivolumab; pembrolizumab; re-challenge; non-small cell lung cancer

Received: June 11, 2018 Accepted: July 21, 2018 Published: August 17, 2018

ABSTRACT

Background: Immune checkpoint inhibitors have dramatically changed lung cancer treatment, demonstrating an overall survival benefit. There are limited data about re-challenge in patients with non-small cell lung cancer. We attempted to address this question for re-challenge of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.

Methods: We retrospectively analyzed 11 patients with advanced non-small cell lung cancer treated with nivolumab and re-challenged with nivolumab/pemblorizumab at Kansai Medical University Hospital from December 2015 to December 2017.

Results: Three patients achieved PR and two patients were in SD. These patients were apt to be good responders to the initial treatment, to develop immune-related adverse events and to be immediately started on re-challenge with immune checkpoint inhibitor. The median PFS was 2.7 (range, 0.5–16.1) months. Five patients (45%) had mild to moderate immune-related adverse events.

Conclusion: Our study shows the effectiveness of re-challenge of immune checkpoint inhibitors in a subset of non-small cell lung cancer patients. Re-challenge might become one of treatment option for advanced non-small cell lung cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25949

Publication Alerts

Research Papers:

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer

Abstract